Ioanna et al. [123] found elevated plasma levels of ANGPTL4 in dry AMD patients suggesting new therapeutic target for dry AMD, a finding consistent with the conclusions of the study of Park and co-workers [124] which investigated the relationship between aqueous ANGPTL4 levels and clinical features in neovascular AMD, and found that ANGPTL4 level was related to the lesion area and the frequency of anti-VEGF treatment. This evidence concerns the gene ANGPTL4 and dry age related macular degeneration.